Does the media favor MLTX or FENC?

In the previous week, MoonLake Immunotherapeutics had 13 more articles in the media than Adherex Technologies. MarketBeat recorded 15 mentions for MoonLake Immunotherapeutics and 2 mentions for Adherex Technologies. Adherex Technologies' average media sentiment score of 0.94 beat MoonLake Immunotherapeutics' score of 0.74 indicating that Adherex Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adherex Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AKTS or FENC?

In the previous week, Aktis Oncology had 3 more articles in the media than Adherex Technologies. MarketBeat recorded 5 mentions for Aktis Oncology and 2 mentions for Adherex Technologies. Aktis Oncology's average media sentiment score of 1.06 beat Adherex Technologies' score of 0.94 indicating that Aktis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aktis Oncology 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adherex Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer FENC or PAHC?

In the previous week, Phibro Animal Health had 2 more articles in the media than Adherex Technologies. MarketBeat recorded 4 mentions for Phibro Animal Health and 2 mentions for Adherex Technologies. Phibro Animal Health's average media sentiment score of 1.59 beat Adherex Technologies' score of 0.94 indicating that Phibro Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adherex Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phibro Animal Health 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to INBX or FENC?

In the previous week, Inhibrx Biosciences and Inhibrx Biosciences both had 2 articles in the media. Inhibrx Biosciences' average media sentiment score of 1.45 beat Adherex Technologies' score of 0.94 indicating that Inhibrx Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adherex Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend NNNN or FENC?

Adherex Technologies has a consensus price target of $15.40, indicating a potential upside of 54.15%. Given Adherex Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Adherex Technologies is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Adherex Technologies 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71

Which has stronger earnings and valuation, NNNN or FENC?

Anbio Biotechnology has higher earnings, but lower revenue than Adherex Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 164.74 $6.40M N/A N/A Adherex Technologies $44.64M 7.84 -$9.74M -$0.29 N/A

Adherex Technologies (FENC) Competitors

$9.99 -0.16 (-1.58%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$9.98 -0.02 (-0.15%)

As of 07/24/2026 07:34 PM Eastern

Compare

FENC vs. MLTX, AKTS, PAHC, INBX, and NNNN

Should you buy Adherex Technologies stock or one of its competitors? MarketBeat compares Adherex Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Adherex Technologies include MoonLake Immunotherapeutics (MLTX), Aktis Oncology (AKTS), Phibro Animal Health (PAHC), Inhibrx Biosciences (INBX), and Anbio Biotechnology (NNNN). These companies are all part of the "pharmaceutical products" industry.

How does Adherex Technologies compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Adherex Technologies (NASDAQ:FENC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

MoonLake Immunotherapeutics presently has a consensus target price of $24.21, suggesting a potential upside of 27.31%. Adherex Technologies has a consensus target price of $15.40, suggesting a potential upside of 54.15%. Given Adherex Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Adherex Technologies is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

MoonLake Immunotherapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market. Comparatively, Adherex Technologies has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Adherex Technologies' net margin of -17.12%. Adherex Technologies' return on equity of -43.87% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%
Adherex Technologies	-17.12%	-43.87%	-11.35%

93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are held by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are held by company insiders. Comparatively, 10.7% of Adherex Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, MoonLake Immunotherapeutics had 13 more articles in the media than Adherex Technologies. MarketBeat recorded 15 mentions for MoonLake Immunotherapeutics and 2 mentions for Adherex Technologies. Adherex Technologies' average media sentiment score of 0.94 beat MoonLake Immunotherapeutics' score of 0.74 indicating that Adherex Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adherex Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adherex Technologies has higher revenue and earnings than MoonLake Immunotherapeutics. Adherex Technologies is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A
Adherex Technologies	$44.64M	7.84	-$9.74M	-$0.29	N/A

Summary

Adherex Technologies beats MoonLake Immunotherapeutics on 11 of the 16 factors compared between the two stocks.

How does Adherex Technologies compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and Adherex Technologies (NASDAQ:FENC) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

Aktis Oncology has a net margin of 0.00% compared to Adherex Technologies' net margin of -17.12%. Aktis Oncology's return on equity of 0.00% beat Adherex Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Adherex Technologies	-17.12%	-43.87%	-11.35%

Adherex Technologies has higher revenue and earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Adherex Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$8.28M	154.14	-$63.73M	-$0.38	N/A
Adherex Technologies	$44.64M	7.84	-$9.74M	-$0.29	N/A

Aktis Oncology currently has a consensus price target of $34.60, suggesting a potential upside of 44.83%. Adherex Technologies has a consensus price target of $15.40, suggesting a potential upside of 54.15%. Given Adherex Technologies' higher probable upside, analysts plainly believe Adherex Technologies is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Aktis Oncology had 3 more articles in the media than Adherex Technologies. MarketBeat recorded 5 mentions for Aktis Oncology and 2 mentions for Adherex Technologies. Aktis Oncology's average media sentiment score of 1.06 beat Adherex Technologies' score of 0.94 indicating that Aktis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aktis Oncology	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adherex Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

28.8% of Aktis Oncology shares are held by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are held by institutional investors. 3.3% of Aktis Oncology shares are held by insiders. Comparatively, 10.7% of Adherex Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Aktis Oncology beats Adherex Technologies on 8 of the 15 factors compared between the two stocks.

How does Adherex Technologies compare to Phibro Animal Health?

Adherex Technologies (NASDAQ:FENC) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

Adherex Technologies currently has a consensus price target of $15.40, suggesting a potential upside of 54.15%. Phibro Animal Health has a consensus price target of $42.50, suggesting a potential upside of 24.89%. Given Adherex Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Adherex Technologies is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Phibro Animal Health has higher revenue and earnings than Adherex Technologies. Adherex Technologies is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adherex Technologies	$44.64M	7.84	-$9.74M	-$0.29	N/A
Phibro Animal Health	$1.30B	1.06	$48.26M	$2.33	14.61

In the previous week, Phibro Animal Health had 2 more articles in the media than Adherex Technologies. MarketBeat recorded 4 mentions for Phibro Animal Health and 2 mentions for Adherex Technologies. Phibro Animal Health's average media sentiment score of 1.59 beat Adherex Technologies' score of 0.94 indicating that Phibro Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adherex Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phibro Animal Health	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

55.5% of Adherex Technologies shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 10.7% of Adherex Technologies shares are held by insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Adherex Technologies has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market. Comparatively, Phibro Animal Health has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market.

Phibro Animal Health has a net margin of 6.35% compared to Adherex Technologies' net margin of -17.12%. Phibro Animal Health's return on equity of 37.14% beat Adherex Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adherex Technologies	-17.12%	-43.87%	-11.35%
Phibro Animal Health	6.35%	37.14%	8.57%

Summary

Phibro Animal Health beats Adherex Technologies on 11 of the 17 factors compared between the two stocks.

How does Adherex Technologies compare to Inhibrx Biosciences?

Inhibrx Biosciences (NASDAQ:INBX) and Adherex Technologies (NASDAQ:FENC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Inhibrx Biosciences has a net margin of 0.00% compared to Adherex Technologies' net margin of -17.12%. Adherex Technologies' return on equity of -43.87% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-72.32%
Adherex Technologies	-17.12%	-43.87%	-11.35%

Inhibrx Biosciences has a beta of 3.41, suggesting that its stock price is 241% more volatile than the broader market. Comparatively, Adherex Technologies has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market.

In the previous week, Inhibrx Biosciences and Inhibrx Biosciences both had 2 articles in the media. Inhibrx Biosciences' average media sentiment score of 1.45 beat Adherex Technologies' score of 0.94 indicating that Inhibrx Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adherex Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

82.5% of Inhibrx Biosciences shares are held by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are held by institutional investors. 18.3% of Inhibrx Biosciences shares are held by company insiders. Comparatively, 10.7% of Adherex Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Adherex Technologies has higher revenue and earnings than Inhibrx Biosciences. Adherex Technologies is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	920.32	-$140.05M	-$8.39	N/A
Adherex Technologies	$44.64M	7.84	-$9.74M	-$0.29	N/A

Inhibrx Biosciences currently has a consensus price target of $150.00, indicating a potential upside of 83.94%. Adherex Technologies has a consensus price target of $15.40, indicating a potential upside of 54.15%. Given Inhibrx Biosciences' higher probable upside, research analysts clearly believe Inhibrx Biosciences is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Inhibrx Biosciences beats Adherex Technologies on 8 of the 15 factors compared between the two stocks.

How does Adherex Technologies compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and Adherex Technologies (NASDAQ:FENC) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Anbio Biotechnology has a net margin of 0.00% compared to Adherex Technologies' net margin of -17.12%. Anbio Biotechnology's return on equity of 0.00% beat Adherex Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Adherex Technologies	-17.12%	-43.87%	-11.35%

Anbio Biotechnology has a beta of 5.15, suggesting that its stock price is 415% more volatile than the broader market. Comparatively, Adherex Technologies has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market.

In the previous week, Anbio Biotechnology and Anbio Biotechnology both had 2 articles in the media. Anbio Biotechnology's average media sentiment score of 1.43 beat Adherex Technologies' score of 0.94 indicating that Anbio Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Anbio Biotechnology	Positive
Adherex Technologies	Positive

55.5% of Adherex Technologies shares are held by institutional investors. 10.7% of Adherex Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Anbio Biotechnology has higher earnings, but lower revenue than Adherex Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	164.74	$6.40M	N/A	N/A
Adherex Technologies	$44.64M	7.84	-$9.74M	-$0.29	N/A

Adherex Technologies has a consensus price target of $15.40, indicating a potential upside of 54.15%. Given Adherex Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Adherex Technologies is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Anbio Biotechnology and Adherex Technologies tied by winning 7 of the 14 factors compared between the two stocks.

Get Adherex Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FENC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FENC vs. The Competition

Export

Metric	Adherex Technologies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$355.60M	$3.67B	$6.88B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-34.45	21.11	27.00	23.71
Price / Sales	7.84	166.46	491.80	74.83
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	9.61	7.88	10.28	6.07
Net Income	-$9.74M	$23.81M	$3.60B	$331.84M
7 Day Performance	-4.86%	-3.79%	-1.25%	-1.53%
1 Month Performance	-5.31%	-2.59%	-0.35%	-2.46%
1 Year Performance	15.76%	32.85%	18.41%	13.66%

Adherex Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FENC Adherex Technologies	4.0261 of 5 stars	$9.99 -1.6%	$15.40 +54.2%	+14.6%	$355.60M	$44.64M	N/A	10	Gap Down
MLTX MoonLake Immunotherapeutics	3.2022 of 5 stars	$19.01 -4.8%	$24.21 +27.4%	-65.4%	$1.47B	N/A	N/A	2	Analyst Revision
AKTS Aktis Oncology	2.3347 of 5 stars	$25.02 -3.8%	$34.60 +38.3%	N/A	$1.39B	$6.50M	N/A	76	News Coverage Positive News Analyst Downgrade
PAHC Phibro Animal Health	4.846 of 5 stars	$34.52 +2.3%	$42.50 +23.1%	+15.6%	$1.37B	$1.30B	14.82	2,475	Positive News
INBX Inhibrx Biosciences	2.7712 of 5 stars	$89.07 -2.4%	$150.00 +68.4%	+253.5%	$1.34B	$1.30M	N/A	166	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FENC) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adherex Technologies (FENC) Competitors

FENC vs. MLTX, AKTS, PAHC, INBX, and NNNN

How does Adherex Technologies compare to MoonLake Immunotherapeutics?

Summary

How does Adherex Technologies compare to Aktis Oncology?

Summary

How does Adherex Technologies compare to Phibro Animal Health?

Summary

How does Adherex Technologies compare to Inhibrx Biosciences?

Summary

How does Adherex Technologies compare to Anbio Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FENC vs. The Competition

Adherex Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adherex Technologies (FENC) Competitors

FENC vs. MLTX, AKTS, PAHC, INBX, and NNNN

How does Adherex Technologies compare to MoonLake Immunotherapeutics?

Do analysts rate MLTX or FENC?

Which has more risk and volatility, MLTX or FENC?

Is MLTX or FENC more profitable?

Do insiders & institutionals hold more shares of MLTX or FENC?

Does the media favor MLTX or FENC?

Which has stronger earnings & valuation, MLTX or FENC?

Summary

How does Adherex Technologies compare to Aktis Oncology?

Is AKTS or FENC more profitable?

Which has higher valuation & earnings, AKTS or FENC?

Do analysts rate AKTS or FENC?

Does the media prefer AKTS or FENC?

Do insiders and institutionals hold more shares of AKTS or FENC?

Summary

How does Adherex Technologies compare to Phibro Animal Health?

Do analysts rate FENC or PAHC?

Which has stronger valuation and earnings, FENC or PAHC?

Does the media prefer FENC or PAHC?

Do institutionals & insiders believe in FENC or PAHC?

Which has more volatility & risk, FENC or PAHC?

Is FENC or PAHC more profitable?

Summary

How does Adherex Technologies compare to Inhibrx Biosciences?

Is INBX or FENC more profitable?

Which has more volatility and risk, INBX or FENC?

Does the media refer more to INBX or FENC?

Do institutionals and insiders have more ownership in INBX or FENC?

Which has stronger earnings and valuation, INBX or FENC?

Do analysts recommend INBX or FENC?

Summary

How does Adherex Technologies compare to Anbio Biotechnology?

Is NNNN or FENC more profitable?

Which has more volatility and risk, NNNN or FENC?

Does the media refer more to NNNN or FENC?

Do institutionals and insiders have more ownership in NNNN or FENC?

Which has stronger earnings and valuation, NNNN or FENC?

Do analysts recommend NNNN or FENC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FENC vs. The Competition

Adherex Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools